Participated · Series B · May 2021

Duality Biologics focuses on developing novel-modality drugs for oncology and autoimmune diseases, with an internal pipeline of nearly 10 best-in-class and first-in-class bispecific antibodies and ADCs. The company has built a next-generation ADC platform with global intellectual property and several candidates validated in preclinical development. Several drug candidates are at the IND stage. DualityBio plans to expand its pipeline through internal R&D as well as strategic in-licensing, out-licensing, and research collaborations globally. The recently completed Series B will fund preclinical research, clinical trials, and pipeline expansion. The company was founded in January 2020 and operates with an international team across China and the United States led by founder and CEO Dr. John Zhu.

Participated · Series A · Sep 2020

Invetx develops protein-based therapeutics for animal health, focusing on fully species-specific monoclonal antibodies for dogs and cats. The company has built an integrated discovery, development and manufacturing platform that generates optimized, half-life extended antibody candidates. It is advancing a broad pipeline across multiple therapeutic areas with several programs in pilot phase and a first product candidate currently in a clinical field study. Invetx plans to advance multiple candidates toward approval and expects product approvals potentially as early as 2025. The company has established collaborations with AbCellera, Twist Bioscience and Wuxi Biologics and a discovery, development and commercialization partnership with Boehringer Ingelheim. Financially, Invetx is well-capitalized following its recent financing and has raised $86 million since 2018 to support continued development and commercialization. Invetx develops protein- and antibody-based therapeutics and a novel discovery platform aimed at veterinary medicine. The company's platform is designed to address a wide range of indications and targets, including challenging targets such as G-protein-coupled receptors (GPCRs). Invetx is initially focused on diseases in dogs and cats and plans to apply its platform to other major veterinary species. The company completed a $25.5 million Series A financing in 2020. Invetx expects to begin pilot studies of its first development candidate in 2020. Recent executive hires and scientific advisors were announced to support antibody and veterinary biologics development. Invetx is building a biotechnology platform focused on protein-based therapeutics for animal health, including antibody medicines. The company aims to translate human biopharma technologies to veterinary applications and is developing a pipeline of recombinant protein therapies. Invetx plans to bring its first pet antibody therapeutic into clinical studies in 2020 and to advance substantial preclinical development across its pipeline. The company has established founding collaborations with WuXi Biologics for development and manufacturing and with AbCellera to accelerate antibody discovery. The $15 million Series A financing will support clinical entry of its lead candidate, expansion of the team, and continued preclinical programs. The global animal health market was estimated at $34 billion in 2019 with forecasted annual growth over six percent, which the company cites as driving demand for new therapeutics.